Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
Allergan, Inc. et al v. Ferrum Ferro Capital, LLC et al
Case Number:
8:15-cv-00992
Court:
Nature of Suit:
Judge:
Firms
Companies
Sectors & Industries:
-
January 20, 2016
Allergan Loses IP Suit Accusing Venture Fund Of Extortion
A California federal judge on Wednesday ended a suit in which Allergan Inc. alleged that Ferrum Ferro Capital LLC's bid to invalidate a patent for a glaucoma drug under the America Invents Act amounted to extortion, after previously finding no subject matter jurisdiction.
-
November 18, 2015
Allergan Slams Fed Preemption Claim In IPR Extortion Row
Allergan Inc. has asked a California federal judge to reject the contention that its extortion claims are preempted by federal law in a suit seeking to block Ferrum Ferro Capital LLC's bid to invalidate a patent for a glaucoma drug, saying Ferrum already missed its chance to make that argument.
-
September 15, 2015
Allergan Fights To Keep IPR Extortion Fight In Federal Court
Allergan Inc. fought to keep its suit alleging Ferrum Ferro Capital LLC's bid to invalidate a patent for a glaucoma drug under the America Invents Act amounts to extortion in California federal court Monday, arguing the issue was vital to establish authority over "for-profit" inter partes reviews.
-
August 11, 2015
Allergan Suit Is SLAPP Retaliation, VC Fund Contends
Ferrum Ferro Capital LLC urged a California federal judge on Monday to toss a lawsuit by Allergan Inc. that calls the venture capital fund's attempt to invalidate a patent on Allergan's glaucoma drug Combigan extortion, saying the suit is retaliation and violates California's anti-SLAPP statutes.
-
June 24, 2015
Allergan Says Venture Fund's AIA Petition Is 'Extortion'
Allergan Inc. has sued Ferrum Ferro Capital LLC in California federal court, claiming the venture fund's attempt to invalidate a patent on Allergan's glaucoma drug Combigan under the America Invents Act is "extortion, pure and simple."